Intrexon (XON) Gets a Hold Rating from Northland Securities

By Austin Angelo

In a report released today, Robert Breza from Northland Securities maintained a Hold rating on Intrexon (XONResearch Report), with a price target of $10. The company’s shares closed on Friday at $6.95.

Breza noted:

“We believe the company will spin-off its assets as the company has backed away from its target cash burn goal of $70M.”

According to TipRanks.com, Breza is a 5-star analyst with an average return of 11.6% and a 56.3% success rate. Breza covers the Technology sector, focusing on stocks such as Coupa Software Inc, MobileIron, Inc., and Salesforce.com.

The word on The Street in general, suggests a Hold analyst consensus rating for Intrexon with a $10 average price target.

See today’s analyst top recommended stocks >>

Based on Intrexon’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $38.77 million. In comparison, last year the company had a GAAP net loss of $65.38 million.

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XON in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intrexon Corp. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals.